Earnings Call Summary | P3 Health Partners(PIII.US) Q4 2023 Earnings Conference
Earnings Call Summary | P3 Health Partners(PIII.US) Q4 2023 Earnings Conference
The following is a summary of the P3 Health Partners Inc. (PIII) Q4 2023 Earnings Call Transcript:
以下是P3 Health Partners Inc.（PIII）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
P3 Health Partners reported a 21% growth in revenue, raising the figure to $1.266 billion in 2023.
PMPM revenue and medical margin also saw substantial growths of 15% and 118% respectively.
Despite an adjusted EBITDA loss of $86 million in 2023, it marked an improvement from the previous year's loss of $128 million.
The company recorded negative $16 million in cash flow used in operations in the fourth quarter, seen as an improvement compared to the year's start.
The company witnessed significant increases in the Oregon and California markets, reflecting in boosts to the year-over-year figures.
P3 Health Partners報告收入增長了21％，在2023年將這一數字提高到12.66億美元。
PMPM收入和醫療利潤率也分別大幅增長了15％和118％。
儘管2023年調整後的息稅折舊攤銷前利潤虧損爲8,600萬美元，但與上一年的1.28億美元虧損相比有所改善。
該公司第四季度用於運營的現金流爲負1600萬美元，與年初相比有所改善。
該公司目睹了俄勒岡州和加利福尼亞州市場的大幅增長，這反映了同比數字的提高。
Business Progress:
業務進展：
The firm experienced a successful annual enrollment period with an 11% increase seen in membership.
They expanded their service areas to a total of 8 new counties across Arizona and Oregon.
Prospects of becoming EBITDA positive are high, with a target of reaching an EBITDA of positive $20 million to $40 million by 2024.
There's a robust pipeline of growth opportunities, and the company envisages positive development across multiple strategic partnerships in the coming quarters.
Various discussions are underway with payers, providers, and health systems, including potential joint venture and strategic partnership opportunities.
Membership and revenue, along with medical margins and adjusted EBITDA, are expected to experience growths in the 2024 fiscal year.
Profitability is projected in the Oregon market for 2024, alongside the intention of adding new health plans in California following profitable growth recorded in 2023.
The ACO REACH program is dedicated to increasing engagements across patient panels, thus enhancing the adoption of value-based care models and their overall performance.
The company witnessed persistent lives improvements from previous years and expects these improvements to contribute significantly to achieving their projected medical margin.
該公司經歷了成功的年度註冊期，會員人數增長了11％。
他們將服務區域擴展到亞利桑那州和俄勒岡州的總共8個新縣。
息稅折舊攤銷前利潤爲正的前景很高，目標是到2024年將息稅折舊攤銷前利潤達到正2,000萬至4000萬美元。
有大量的增長機會，該公司預計在未來幾個季度中，多個戰略合作伙伴關係將取得積極的發展。
正在與付款人、提供者和衛生系統進行各種討論，包括潛在的合資企業和戰略合作機會。
預計會員和收入以及醫療利潤率和調整後的息稅折舊攤銷前利潤將在2024財年實現增長。
預計俄勒岡州市場將在2024年實現盈利，並打算在2023年實現盈利增長之後在加利福尼亞增加新的健康計劃。
ACO REACH計劃致力於增加患者小組的參與度，從而提高基於價值的護理模式的採用及其整體績效。
與往年相比，該公司的生活水平持續改善，並預計這些改善將爲實現其預期的醫療利潤做出重大貢獻。
More details: P3 Health Partners IR
更多詳情： P3 健康合作伙伴 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。